- Previous Close
20.36 - Open
20.52 - Bid 20.22 x 100
- Ask 20.48 x 100
- Day's Range
19.25 - 21.11 - 52 Week Range
16.56 - 28.15 - Volume
515,650 - Avg. Volume
608,856 - Market Cap (intraday)
1.477B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.60 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.86
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
www.kiniksa.com315
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KNSA
View MorePerformance Overview: KNSA
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KNSA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KNSA
View MoreValuation Measures
Market Cap
1.48B
Enterprise Value
1.24B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.43
Price/Book (mrq)
3.37
Enterprise Value/Revenue
2.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.20%
Return on Assets (ttm)
-5.15%
Return on Equity (ttm)
-9.85%
Revenue (ttm)
423.24M
Net Income Avi to Common (ttm)
-43.19M
Diluted EPS (ttm)
-0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
243.63M
Total Debt/Equity (mrq)
2.25%
Levered Free Cash Flow (ttm)
22.57M